Lumida
/CORT
⌘K
Corcept Therapeutics Inc

Corcept Therapeutics Inc

CORT
$90.52USD↑+0.89%+0.80 today

MARKET CAP

9.7B

P/E (TTM)

258.6x

FWD P/E

71.4x

DAY RANGE

$87 – $91

52W RANGE

$29
$95

AI Summary

Stalk
Buy NowMedium

CORT remains in a Stage 2 advance marked by higher highs and higher lows. After peaking at overbought levels, price has pulled back into the rising 9 and 21 EMA zone and is holding above support. EMAs are positively sloped and layered, RSI has eased from overbought into neutral territory, and volume patterns remain healthy. The speculative strategy supports a tactical pullback entry into dynamic support.

  • ↑Relacorilant FDA approved ahead of schedule, projected >$1B revenue by 2030.
  • ↑2026 revenue guidance raised to $950M–$1.05B after strong clinical results.
  • ↓Q1 net loss $31.8M vs $20.5M profit year ago indicates loss pressure.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Corcept Therapeutics Inc. (NASDAQ: CORT) is a biopharmaceutical company specializing in the development of innovative therapies that modulate cortisol to treat various severe metabolic and oncological conditions, with a focus on hypercortisolism and oncology. The company is positioned favorably in the growing niche of cortisol modulation, having recently received FDA approval for its ovarian cancer drug, Relacorilant (marketed as Lifyorli), which enhances its competitive edge in the oncology treatment landscape.

Bull says

  • ↑Relacorilant FDA approved ahead of schedule, projected >$1B revenue by 2030.
  • ↑2026 revenue guidance raised to $950M–$1.05B after strong clinical results.
  • ↑Q1 revenue $164.9M up 5% YoY; cash position $515M provides liquidity.
  • ↑Analysts raising earnings forecasts reflecting efficient operations and strong momentum.
  • ↑New specialty pharmacy partnership resolves supply constraints to boost sales.
  • ↑Multiple Phase III oncology trials support long-term pipeline growth.

Bear says

  • ↓Q1 net loss $31.8M vs $20.5M profit year ago indicates loss pressure.
  • ↓FDA issued CRL for Relacorilant NDA, risking approval delays and costs.
  • ↓Patent litigation with Teva risks generic entry and share erosion.
  • ↓Specialty pharmacy transition causing treatment fulfillment challenges and revenue volatility.
  • ↓Insurance reauthorizations and prescriber hesitance may slow patient adoption.
  • ↓Premium valuation with weak institutional ownership suggests overvaluation risks.

Investment themes with CORT

Pharmaceuticals↓ -1.67%

Drug development driving global healthcare solutions

JNJ · LLY · RPRX

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-01-2026neutral

Transcript signals

Bull points

  • Our revenue in the first quarter of 2026 was $164.9 million, compared to $157.2 million in the prior year period.
  • We have increased our 2026 revenue guidance to $950 million to $1.05 billion.
  • Liviorli's FDA approval in platinum-resistant ovarian cancer indicates that reducing cortisol activity at the glucocorticoid receptor, GR, may be beneficial in treating a wide variety of solid tumors.

Bear points

  • Net loss was $31.8 million in the first quarter of 2026 compared to net income of $20.5 million in the first quarter of last year.
  • Non-serious GI distress caused most of the discontinuations in DASLs, an outcome that we think can be avoided.
  • First, revenue often dips in the first quarter, as it does for many rare disease medications, because insurance companies impose onerous reauthorization procedures at the start of each year that interrupt patient coverage for a month or two.
Read full transcript analysis ›